Xilio Therapeutics Inc (XLO) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

Phase 1 combination dose escalation expected to support planned Phase 2 trial in microsatellite stable...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

Demonstrated initial clinical validation of tumor-selective activation technology for both XTX101, a...

Form 8-K - Current report

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses (≥2.8...

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage...

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities